Stay updated on Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page.

Latest updates to the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page history shows Revision: v3.4.2 in place of v3.4.1 in the footer, indicating a minor site update. This change does not affect study data or user-facing functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedThe history now includes a new site revision label v3.4.1 and removes v3.4.0. This is a minor platform update and does not affect study data or record content.SummaryDifference0.1%

- Check27 days agoChange DetectedThe history page now includes a glossary toggle, color-coded highlights (green for additions, red for deletions), and an updated Revision: v3.4.0 label along with wording changes to No FEAR Act data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check42 days agoChange DetectedThe revision history now includes a new entry for v3.3.4 and removes v3.3.3 from the list, representing a minor update to the record's revision history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedFooter changes include the addition of 'Revision: v3.3.3' and removal of the 'HHS Vulnerability Disclosure' link and the 'Revision: v3.3.2' entry. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check85 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2 on the page header, indicating a minor site update.SummaryDifference0.1%

Stay in the know with updates to Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page.